Case number 2018-2362
Genzyme Corporation v. Zydus Pharmaceuticals (USA) > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | GENZYME CORPORATION v. ZYDUS PHARMACEUTICALS (USA) [RULE 36 JUDGMENT] [nonprecedential] (0) |
| Nov 25, 2019 | 69 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [652158] [JAB] [Entered: 11/25/2019 02:41 PM] (1) |
| Nov 18, 2019 | 68 | ORDER filed denying [63] petition for panel rehearing, petition for en banc rehearing filed by Zydus Pharmaceuticals (USA) Inc. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [649920] [JAB] [Entered: 11/18/2019 09:57 AM] (2) |
| Nov 4, 2019 | 67 | 18 paper copies of the response [66] received from Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. [646681] [JAB] [Entered: 11/04/2019 01:11 PM] (0) |
| Oct 31, 2019 | 66 | RESPONSE of Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC to the petition [63] filed by Appellant Zydus Pharmaceuticals (USA) Inc., petition [63] filed by Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 10/31/2019 by email. [646162] [18-2362] [James Lovsin] [Entered: 10/31/2019 02:25 PM] (29) |
| Oct 17, 2019 | 65 | The court invites a response from Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC to the petition for panel rehearing, petition for en banc rehearing filed by Appellant in 18-2362. The response is due on or before 10/31/2019. [642862] [JAB] [Entered: 10/17/2019 12:19 PM] (1) |
| Sep 17, 2019 | 64 | 18 paper copies of the petition for en banc rehearing [63], petition for panel rehearing [63] received from Appellant Zydus Pharmaceuticals (USA) Inc. [636084] [JAB] [Entered: 09/17/2019 12:38 PM] (0) |
| Sep 16, 2019 | 63 | Petition for en banc rehearing, for panel rehearing filed by Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 09/16/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 09/18/2019 [635822] [18-2362] [Chad Landmon] [Entered: 09/16/2019 02:32 PM] (32) |
| Aug 16, 2019 | 62 | JUDGMENT. AFFIRMED. Issued pursuant to Federal Circuit Rule 36. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [628849] [JAB] [Entered: 08/16/2019 09:59 AM] (2) |
| Aug 7, 2019 | 61 | Submitted after ORAL ARGUMENT by Chad A. Landmon for Zydus Pharmaceuticals (USA) Inc. and Mr. Paul Henry Berghoff for Genzyme Corporation and Sanofi-Aventis U.S., LLC. Panel: Judge: Newman , Judge: Chen , Judge: Hughes. [626615] [JCP] [Entered: 08/07/2019 10:56 AM] (0) |
| Jul 25, 2019 | 60 | **TEXT ONLY** ORDER granting motion to withdraw attorney Paula S. Fritsch [59] filed by Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [623490] [JAB] [Entered: 07/25/2019 01:29 PM] (0) |
| Jul 25, 2019 | 59 | MOTION of Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC to withdraw counsel Paula S. Fritsch [Consent: unopposed]. Service: 07/25/2019 by email. [623435] [18-2362] [James Lovsin] [Entered: 07/25/2019 11:16 AM] (6) |
| Jul 25, 2019 | 58 | Amended Certificate of Interest for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 07/25/2019 by email. [623430] [18-2362] [James Lovsin] [Entered: 07/25/2019 11:09 AM] (3) |
| Jul 15, 2019 | 57 | Response to notice of oral argument from the Appellant Zydus Pharmaceuticals (USA) Inc.. [620969] [18-2362] [Chad Landmon] [Entered: 07/15/2019 02:25 PM] (3) |
| Jul 11, 2019 | 56 | Response to notice of oral argument from the Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. [620414] [18-2362] [Daniel Gelwicks] [Entered: 07/11/2019 04:41 PM] (3) |
| Jun 21, 2019 | 55 | NOTICE OF ORAL ARGUMENT. Panel: 1908H. Case scheduled August 07, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 402. Response to Notice of Oral Argument due: 07/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [616195] [MJL] [Entered: 06/21/2019 05:39 PM] (2) |
| Mar 18, 2019 | 53 | Notice from Appellant Zydus Pharmaceuticals (USA) Inc. regarding conflicts with oral argument. Service: 03/18/2019 by email. [593631] [18-2362] [Chad Landmon] [Entered: 03/18/2019 03:03 PM] (3) |
| Mar 18, 2019 | 52 | 6 paper copies of the Opening Response Brief [36] received from Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. [593536] [CJF] [Entered: 03/18/2019 11:42 AM] (0) |
| Mar 14, 2019 | 51 | 6 paper copies of the Reply Brief [43] received from Appellant Zydus Pharmaceuticals (USA) Inc.. [592942] [CJF] [Entered: 03/14/2019 04:12 PM] (0) |
| Mar 14, 2019 | 50 | 6 paper copies of the Appendix Brief (Vol. I - II) [46] received from Appellant Zydus Pharmaceuticals (USA) Inc. and Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. [592810] [CJF] [Entered: 03/14/2019 11:39 AM] (0) |
| Mar 13, 2019 | 49 | Notice from Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC regarding conflicts with oral argument. None. Service: 03/13/2019 by email. [592603] [18-2362] [Daniel Gelwicks] [Entered: 03/13/2019 02:53 PM] (2) |
| Mar 12, 2019 | 48 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The notice of conflict with oral argument is due on or before 03/19/2019. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [592207] [MMA] [Entered: 03/12/2019 02:08 PM] (1) |
| Mar 12, 2019 | 47 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [592206] [MMA] [Entered: 03/12/2019 02:08 PM] (0) |
| Mar 6, 2019 | 46 | MODIFIED ENTRY: APPENDIX FILED for Zydus Pharmaceuticals (USA) Inc. and Genzyme Corporation and Sanofi-Aventis U.S., LLC. Number of Pages: 873. Service: 03/06/2019 by email. [590954] --[Edited 03/12/2019 by MMA - Reason: compliance review complete] [Chad Landmon] [Entered: 03/06/2019 07:23 PM] (873) |
| Mar 6, 2019 | 45 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 03/06/2019 by email. [590949] [18-2362] [James Lovsin] [Entered: 03/06/2019 06:21 PM] (3) |
| Mar 6, 2019 | 44 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 03/06/2019 by email. [590860] [18-2362] [Chad Landmon] [Entered: 03/06/2019 03:14 PM] (3) |
| Feb 27, 2019 | 43 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellant Zydus Pharmaceuticals (USA) Inc. Number of Pages: 31. Service: 02/27/2019 by email. [589048] --[Edited 03/12/2019 by MMA - Reason: compliance review complete] [Chad Landmon] [Entered: 02/27/2019 12:49 PM] (42) |
| Feb 1, 2019 | 42 | **TEXT ONLY** ORDER granting motion to extend time to file brief [40] filed by Appellant Zydus Pharmaceuticals (USA) Inc. Appellant's reply brief is due 02/27/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [582791] [MMA] [Entered: 02/01/2019 12:51 PM] (0) |
| Jan 30, 2019 | 41 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellant Zydus Pharmaceuticals (USA) Inc. and Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 01/30/2019 by email. [582211] [18-2362] [Chad Landmon] [Entered: 01/30/2019 04:09 PM] (3) |
| Jan 30, 2019 | 40 | MOTION of Appellant Zydus Pharmaceuticals (USA) Inc. to extend the time to 02/27/2019 [Consent: unopposed]. Service: 01/30/2019 by email. [582209] [18-2362] [Chad Landmon] [Entered: 01/30/2019 04:06 PM] (9) |
| Jan 30, 2019 | 39 | Amended Certificate of Interest for the Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 01/30/2019 by email. [582206] [18-2362] [Chad Landmon] [Entered: 01/30/2019 04:02 PM] (3) |
| Jan 29, 2019 | 38 | Amended Certificate of Interest for the Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 01/29/2019 by email. [581925] [18-2362] [James Lovsin] [Entered: 01/29/2019 06:13 PM] (3) |
| Jan 28, 2019 | 37 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:Opening Response Brief Docket No. [36], ERROR: The information on the Certificate of Interest (COI) included in the brief does not match the information on the COI entered on the docket. CORRECTION: Pursuant to FCR 47.4(c), please file an amended Certificate of Interest as a separate docket entry. [581433] [MMA] [Entered: 01/28/2019 01:59 PM] (0) |
| Jan 22, 2019 | 36 | MODIFIED ENTRY: BRIEF FILED for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Number of Pages: 62. Service: 01/22/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [579958] --[Edited 01/28/2019 by MMA - Reason: compliance review complete] [James Lovsin] [Entered: 01/22/2019 08:49 PM] (79) |
| Nov 29, 2018 | 35 | 6 paper copies of the Opening Brief [33] received from Appellant Zydus Pharmaceuticals (USA) Inc.. [568506] [CJF] [Entered: 11/29/2018 11:56 AM] (0) |
| Nov 27, 2018 | 34 | **TEXT ONLY** ORDER granting motion to extend time to file brief [32] filed by Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC brief is due 01/22/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [567924] [JB] [Entered: 11/27/2018 02:45 PM] (0) |
| Nov 21, 2018 | 32 | MOTION of Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC to extend the time to 01/22/2019 to file the Appellees' brief. [Consent: unopposed]. Service: 11/21/2018 by email. [567275] [18-2362] [James Lovsin] [Entered: 11/21/2018 10:19 PM] (9) |
| Nov 13, 2018 | 33 | BRIEF FILED for Appellant Zydus Pharmaceuticals (USA) Inc. [31]. Number of Pages: 67. Service: 11/13/2018 by email. Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC brief is due 12/26/2018. [567919] [JB] [Entered: 11/27/2018 02:39 PM] (242) |
| Nov 13, 2018 | 31 | TENDERED from Appellant Zydus Pharmaceuticals (USA) Inc.. Title: OPENING BRIEF. Service: 11/13/2018 by email. [564639] [18-2362] [Chad Landmon] [Entered: 11/13/2018 05:48 PM] (242) |
| Nov 13, 2018 | 30 | Entry of appearance for Dan Feng Mei as of counsel for Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 11/12/2018 by email. [564150] [18-2362] [Dan-Feng Mei] [Entered: 11/12/2018 03:09 PM] (2) |
| Nov 9, 2018 | 29 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [563984] [JB] [Entered: 11/09/2018 02:55 PM] (0) |
| Oct 30, 2018 | 28 | Corrected Entry of appearance for Daniel F. Gelwicks as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 10/30/2018 by email. [561491] [18-2362] [Daniel Gelwicks] [Entered: 10/30/2018 06:23 PM] (2) |
| Oct 30, 2018 | 27 | Entry of appearance for Daniel F. Gelwicks as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 10/30/2018 by email. [561490] [18-2362] [Daniel Gelwicks] [Entered: 10/30/2018 06:14 PM] (2) |
| Oct 1, 2018 | 26 | Corrected Entry of appearance for Edward M. Mathias as of counsel for Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 10/01/2018 by email. [553774] [18-2362] [Edward Mathias] [Entered: 10/01/2018 03:22 PM] (2) |
| Oct 1, 2018 | 25 | Corrected Entry of appearance for David K. Ludwig as of counsel for Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 10/01/2018 by email. [553773] [18-2362] [David Ludwig] [Entered: 10/01/2018 03:20 PM] (2) |
| Oct 1, 2018 | 24 | Corrected Certificate of Interest for the Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 10/01/2018 by email. [553772] [18-2362] [Chad Landmon] [Entered: 10/01/2018 03:17 PM] (3) |
| Oct 1, 2018 | 23 | Entry of appearance for Chad A. Landmon as principal counsel for Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 10/01/2018 by email. [553771] [18-2362] [Chad Landmon] [Entered: 10/01/2018 03:16 PM] (2) |
| Sep 28, 2018 | 22 | Entry of appearance for Jeremy E. Noe as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553331] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:40 PM] (2) |
| Sep 28, 2018 | 21 | Entry of appearance for Kurt W. Rohde as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553330] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:38 PM] (2) |
| Sep 28, 2018 | 20 | Entry of appearance for Nathaniel P. Chongsiriwatana as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553328] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:37 PM] (2) |
| Sep 28, 2018 | 19 | Entry of appearance for Nicole E. Grimm as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553326] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:35 PM] (2) |
| Sep 28, 2018 | 18 | Entry of appearance for Jeffrey B. Bove as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553324] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:34 PM] (2) |
| Sep 28, 2018 | 17 | Entry of appearance for James L. Lovsin as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553322] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:32 PM] (2) |
| Sep 28, 2018 | 16 | Docketing Statement for the Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553321] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:31 PM] (4) |
| Sep 28, 2018 | 15 | Entry of appearance for Alison J. Baldwin as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553319] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:30 PM] (2) |
| Sep 28, 2018 | 14 | Entry of appearance for Paul H. Berghoff as principal counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553318] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:29 PM] (2) |
| Sep 28, 2018 | 13 | Entry of appearance for Paula S. Fritsch as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 09/28/2018 by email. [553317] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:27 PM] (2) |
| Sep 28, 2018 | 12 | Certificate of Interest for the Appellees Sanofi-Aventis U.S., LLC and Genzyme Corporation. Service: 09/28/2018 by email. [553315] [18-2362] [Paula Fritsch] [Entered: 09/28/2018 01:25 PM] (3) |
| Sep 28, 2018 | 11 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Zydus Pharmaceuticals (USA) Inc., Certificates of Interest and Entries of Appearance - Appellant [9], [8], [7], [5], [4], [3], [2], is not in compliance with the rules of this court (see attached). Compliant documents due on 10/05/2018. Service as of this date by the Clerk of Court.[553256] [MMA] [Entered: 09/28/2018 11:35 AM] (2) |
| Sep 27, 2018 | 10 | Docketing Statement for the Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 09/27/2018 by email. [553045] [18-2362] [Chad Landmon] [Entered: 09/27/2018 02:58 PM] (3) |
| Sep 27, 2018 | 9 | Certificate of Interest for the Appellant Zydus Pharmaceuticals (USA) Inc. Service: 09/27/2018 by email. [553042] [18-2362]. This document is non-compliant. See Doc. No.[11] [Chad Landmon] [Entered: 09/27/2018 02:57 PM] (2) |
| Sep 27, 2018 | 8 | Entry of appearance for Chad A. Landmon as principal counsel for Appellant Zydus Pharmaceuticals (USA) Inc. Service: 09/27/2018 by email. [553041] [18-2362]. This document is non-compliant. See Doc. No.[11] [Chad Landmon] [Entered: 09/27/2018 02:56 PM] (1) |
| Sep 27, 2018 | 7 | Entry of appearance for Edward M. Mathias as of counsel for Appellant Zydus Pharmaceuticals (USA) Inc. Service: 09/27/2018 by email. [553039] [18-2362]. This document is non-compliant. See Doc. No.[11] [Edward Mathias] [Entered: 09/27/2018 02:54 PM] (1) |
| Sep 27, 2018 | 6 | Docketing Statement for the Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 09/27/2018 by email. [553028] [18-2362] [David Ludwig] [Entered: 09/27/2018 02:30 PM] (3) |
| Sep 27, 2018 | 5 | Certificate of Interest for the Appellant Zydus Pharmaceuticals (USA) Inc. Service: 09/27/2018 by email. [553027] [18-2362]. This document is non-compliant. See Doc. No.[11] [David Ludwig] [Entered: 09/27/2018 02:28 PM] (2) |
| Sep 27, 2018 | 4 | Entry of appearance for David K. Ludwig as of counsel for Appellant Zydus Pharmaceuticals (USA) Inc. Service: 09/27/2018 by email. [553025] [18-2362]. This document is non-compliant. See Doc. No.[11] [David Ludwig] [Entered: 09/27/2018 02:26 PM] (1) |
| Sep 27, 2018 | 3 | Entry of appearance for Edward M. Mathias as of counsel for Appellant Zydus Pharmaceuticals (USA) Inc. Service: 09/27/2018 by email. [553022] [18-2362]. This document is non-compliant. See Doc. No.[11] [David Ludwig] [Entered: 09/27/2018 02:25 PM] (1) |
| Sep 27, 2018 | 2 | Entry of appearance for Chad A. Landmon as principal counsel for Appellant Zydus Pharmaceuticals (USA) Inc. Service: 09/27/2018 by email. [553018] [18-2362]. This document is non-compliant. See Doc. No.[11] [David Ludwig] [Entered: 09/27/2018 02:22 PM] (1) |
| Sep 14, 2018 | 1 | Appeal docketed. Received: 09/06/2018. [549792]Entry of Appearance due 09/28/2018. Certificate of Interest is due on 09/28/2018. Docketing Statement due 09/28/2018. Appellant/Petitioner's brief is due 11/13/2018. [JB] [Entered: 09/14/2018 11:22 AM] (21) |
